Secarna Pharmaceuticals
Secarna Pharmaceuticals GmbH & Co. KG is a biotechnology company specializing in the discovery and development of best-in-class oligonucleotide therapeutics using its proprietary AI-empowered OligoCreator® platform. This platform integrates various delivery technologies to identify and characterize oligonucleotide therapies with high speed, safety, and efficacy, targeting specific cells, organs, or tissues. Secarna focuses on developing innovative drug candidates that have the potential to be first-in-class or best-in-class for difficult-to-treat disorders, including immuno-oncology, ophthalmology, immunology, fibrotic diseases, and anti-viral applications. Their lead program, SECN-15, is an antisense oligonucleotide targeting Neuropilin-1 (NRP1) for solid cancers, currently advancing towards Phase I/II clinical trials. The company operates globally from its base in Germany and collaborates strategically with partners to advance its pipeline and scientific discoveries.
Secarna Pharmaceuticals
Secarna Pharmaceuticals GmbH & Co. KG is a biotechnology company specializing in the discovery and development of best-in-class oligonucleotide therapeutics using its proprietary AI-empowered OligoCreator® platform. This platform integrates various delivery technologies to identify and characterize oligonucleotide therapies with high speed, safety, and efficacy, targeting specific cells, organs, or tissues. Secarna focuses on developing innovative drug candidates that have the potential to be first-in-class or best-in-class for difficult-to-treat disorders, including immuno-oncology, ophthalmology, immunology, fibrotic diseases, and anti-viral applications. Their lead program, SECN-15, is an antisense oligonucleotide targeting Neuropilin-1 (NRP1) for solid cancers, currently advancing towards Phase I/II clinical trials. The company operates globally from its base in Germany and collaborates strategically with partners to advance its pipeline and scientific discoveries.